Rare Opportunity (EPOC, BIOL, CNMX, MCP)

Los Angelas, CA -- (SBWIRE) -- 01/08/2013 -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Epocrates, Inc. (NASDAQ:EPOC) relating to the proposed acquisition by AthenaHealth, Inc. Under the terms of the transaction, Epocrates shareholders will receive only $11.75 in cash for each share of Epocrates stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Epocrates for not acting in the Company's shareholders' best interests in connection with the sale process to AthenaHealth. The transaction may undervalue the Company and will result in a loss for many shareholders.

Should Investor Book Profit and Exit From EPOC: Need Instant Reply Check Here

BIOLASE, Inc. (NASDAQ:BIOL), the world's leading dental laser manufacturer and distributor, announced today that, based on a preliminary review of its financial performance for the fourth quarter ended December 31, 2012, the Company expects to exceed its previous guidance and report net revenue in excess of $18 million. Federico Pignatelli, Chairman and CEO of BIOLASE, said, "We are very pleased with the strong growth in our core dental laser products and the trends that are accelerating with the adoption of our WaterLase® technology and diode laser systems. Our strong revenue growth in the 2012 fourth quarter compared to the prior year period was primarily due to the increased demand for our flagship WaterLase iPlus™ and our new EPIC 10™ soft tissue diode laser. Revenues were also bolstered by sales of our mid-priced WaterLase products and our digital imaging products, including the initial sales of our CAD/CAM systems."

Ready To Get Instant Analysis Report From Here: Just Check Now

CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it expects to report record volumes of prenatal testing in the fourth quarter and year ended December 31, 2012. Preliminary annual growth rates of 172 percent and 171 percent were achieved for billable prenatal tests in the quarter and full year, respectively. The rapid growth rate in prenatal testing, which includes both prenatal and miscarriage testing, is the result of the Company's strategic shift to focus on its prenatal molecular diagnostics testing markets, where the Company believes that chromosomal microarray analysis (CMA) is becoming the standard of care.

How Should Investors React to CBMX Now? Find Out Here

Molycorp’s (NYSE:MCP) fall below the value of its net assets is turning the company into a takeover target. The firm owns a rare Earth supply unrivaled in the Western hemisphere and also comprises the largest domestic deposit of metals that go into smartphones, solar panels and hybrid cars. It gave investors losses of 61 percent in 2012 during a slump in rare Earth prices, expense overruns at its California mine, a regulatory inquiry and the exit of its chief executive officer. Shares rebounded from a record low in November, but they are trading at a 19 percent discount to its book value, says data compiled by Bloomberg.

Are These Stock Buy or Sell? Get a Current Trend Analysis Report From Here

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

Contact:
hotpennystocknews.com
info@hotpennystocknews.com